drugset / Trial / NCT06907615
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
Timeline
- Start
- 2025-06-09
- Primary completion
- 2028-04-20
- Completion
- 2028-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX43 | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | HLX43 | Other / unclassified | 2.5 mg/kg | Intravenous |